EUVIMEDEUVIMED entdecken
Open Access

A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus

Melissa E Munroe iD, Derek Blankenship, Daniele DeFreese, Mohan Purushothaman, Wade DeJager, Susan Macwana, Joel M Guthridge, Stan Kamp, Nancy Redinger, Teresa Aberle, Eliza F Chakravarty, Cristina Arriens iD und 7 weitere

Arthritis & Rheumatology · 2023-05 · 75 (5) · 723-735

DOI: 10.1002/art.42389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 06.03.2023. Verfasst von Melissa E Munroe und 18 weiteren Autor:innen. Beteiligte Einrichtung: Progentec Diagnostics, Inc., and Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City. Hauptthemen laut MEDLINE: Immunologic Factors, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAMS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Systemic lupus erythematosus (SLE) is marked by immune dysregulation linked to varied clinical disease activity. Using a unique longitudinal cohort of SLE patients, this study sought to identify optimal immune mediators informing an empirically refined flare risk index (FRI) reflecting altered immunity prior to clinical disease flare.

Methods

Thirty‐seven SLE‐associated plasma mediators were evaluated by microfluidic immunoassay in 46 samples obtained in SLE patients with an imminent clinical disease flare (preflare) and 53 samples obtained in SLE patients without a flare over a corresponding period (pre‐nonflare). SLE patients were selected from a unique longitudinal cohort of 106 patients with classified SLE (meeting the American College of Rheumatology 1997 revised criteria for SLE or the Systemic Lupus International Collaborating Clinics 2012 revised criteria for SLE). Autoantibody specificities, hybrid SLE Disease Activity Index (hSLEDAI) scores, clinical features, and medication usage were also compared at preflare (mean ± SD 111 ± 47 days prior to flare) versus pre‐nonflare (99 ± 21 days prior to nonflare) time points. Variable importance was determined by random forest analysis with logistic regression subsequently applied to determine the optimal number and type of analytes informing a refined FRI.

Results

Preflare versus pre‐nonflare differences were not associated with demographics, autoantibody specificities, hSLEDAI scores, clinical features, nor medication usage. Forward selection and backward elimination of mediators ranked by variable importance resulted in 17 plasma mediator candidates differentiating preflare from pre‐nonflare visits. A final combination of 11 mediators best informed a newly refined FRI, which achieved a maximum sensitivity of 97% and maximum specificity of 98% after applying decision curve analysis to define low, medium, and high FRI scores.

Conclusion

We verified altered immune mediators associated with imminent disease flare, and a subset of these mediators improved the FRI to identify SLE patients at risk of imminent flare. This molecularly informed, proactive management approach could be critical in prospective clinical trials and the clinical management of lupus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunologic FactorsLupus Erythematosus, SystemicHumansProspective StudiesSymptom Flare UpAutoantibodiesSeverity of Illness Index

Substanzen

Immunologic FactorsAutoantibodies

Autor:innen und Institutionen

  • Progentec Diagnostics, Inc., and Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City.
  • DB Analytics, LLC, Dallas, Texas.
  • Progentec Diagnostics, Inc., Oklahoma City, Oklahoma.
  • Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City.
  • Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City.
  • Division of Rheumatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.

ORCID-Profile: Melissa E Munroe, Cristina Arriens, Hu Zeng, Judith A James

Förderung

  • NIGMS NIH HHS
  • NIAMS NIH HHS
  • NIAID NIH HHS
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • National Institute of Allergy and Infectious Diseases
  • National Institute of General Medical Sciences
  • Oklahoma Center for the Advancement of Science and Technology

Zitieren

APA

Munroe, M. E., Blankenship, D., DeFreese, D., Purushothaman, M., DeJager, W., Macwana, S., Guthridge, J. M., Kamp, S., Redinger, N., Aberle, T., Chakravarty, E. F., Arriens, C., Li, Y., Zeng, H., McCarthy-Fruin, K. A., Osei-Onomahm, S. A., Thanarajasingam, U., James, J. A., & Jupe, E. (2023). A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus. Arthritis & Rheumatology, 75(5), 723-735. https://doi.org/10.1002/art.42389

Vancouver

Munroe ME, Blankenship D, DeFreese D, Purushothaman M, DeJager W, Macwana S, et al. A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus. Arthritis & Rheumatology. 2023;75(5):723-735. doi:10.1002/art.42389

BibTeX
@article{Munroe2023,
  author = {Munroe, Melissa E and Blankenship, Derek and DeFreese, Daniele and Purushothaman, Mohan and DeJager, Wade and Macwana, Susan and Guthridge, Joel M and Kamp, Stan and Redinger, Nancy and Aberle, Teresa and Chakravarty, Eliza F and Arriens, Cristina and Li, Yanfeng and Zeng, Hu and McCarthy-Fruin, Kathleen A and Osei-Onomahm, Shirley-Ann and Thanarajasingam, Uma and James, Judith A and Jupe, Eldon},
  title = {A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus},
  journal = {Arthritis & Rheumatology},
  year = {2023},
  volume = {75},
  number = {5},
  pages = {723--735},
  doi = {10.1002/art.42389}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche